Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : BRLI-- A substantially undervalued micro-cap -- Ignore unavailable to you. Want to Upgrade?

To: LawStor who wrote (94)	2/13/1999 11:24:00 AM
From: jmhollen	Read Replies (1) \| Respond to of 105

Hello, I just got a BRLI blurb from one of my advisory services: *********************************************** STOCKFIRST would like to bring you an update on BRLI. RECORD REVENUES Great news on Bio-Reference Laboratories, Inc. (Nasdaq small cap - BRLI). This was Stockfirst's January Profile at $1.21. Approximate current stock price bid $1.375 offer at $1.40625. Today BRLI announced record revenues with over a 20% increase in revenues for fiscal year ended October 31, 1998. Revenues - Fiscal Year 1998 $46,553,730 Revenues - Fiscal Year 1997 $38,660,184 Increase in Revenue from 1997 to 1998 $7,893,546 (over 20%) HIGH VALUATIONS Another highlight of today's announcement is the comparison Dr. Marc Grodman, President and Chief Executive Officer, made regarding a recent transaction between Quest Diagnostics and the purchase of the clinical laboratory unit of Smith-Kline Beechman, PLC. Here Dr. Grodman stated that "Quest Diagnostic made the purchase for a value of over 90% of annual revenues." News headlines from February 9, 1999 - "Quest Diagnostics to Acquire Smith-Kline Beecham Clinical Laboratories for 1.3 Billion in cash and stock on $1.6 Billion in Revenues." Dr. Grodman continued "this shows there is a significant disparity between public market valuation of clinical laboratories and the values upon which transactions with the industry are based." We at Stockfirst continue to believe this is an undervalued situation. For the full detailed report from the company, click the URL below stockfirst.com ***************************************************** I think I'll get involved on Monday. John :-) ps: since I just butted in, I'll share a little of what I know. >> O/T << - for those with other than "Bio" interests: LGOV is looking good for a run the first week of March. BETT is going to have news out soon, fueling another run. In addition you can buy shares from the company [form 144 or something] at half the current value - marketable in Apr+/-. IMHO this definitely falls into the "..such a deal.." category.